Development of a Disease Severity and Responder Index for Psoriatic Arthritis (PsA) — Report of the OMERACT 10 PsA Special Interest Group

Work within the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) to develop and validate composite disease activity measures in PsA has progressed. At the Outcome Measures in Rheumatology Clinical Trials (OMERACT) 8 meeting, a core set of domains to be assessed in randomized controlled trials (RCT) and longitudinal observational studies (LOS) of PsA was agreed upon. At OMERACT 10, work to date regarding proposed composite responder indices was presented. Five proposed composite responder definitions for PsA were reviewed and discussed including new data from the GRACE (GRAppa Composite Exercise) study. There was agreement that the work to date was promising, and that developing composite outcome measures for use in RCT and LOS was important. Further work was required, including data on followup timepoints and less common phenotypes of PsA, to ensure that all subgroups were represented within GRACE. During discussion on the concept of composite measures for PsA, based on predominant/little/no involvement in several domains (such as skin versus joints, enthesitis, dactylitis, spondyloarthritis) it was acknowledged that a simple summative score encompassing all domains of PsA would be difficult to construct psychometrically and may not be appropriate. Ideally, any composite measure should retain the ability to differentiate between activity in individual domains, such as enthesitis or skin psoriasis, so that the influence of each can be assessed independently. Further work is required within the GRACE dataset to develop an optimal composite measure for PsA. Several proposals to date have shown preliminary validity according to the OMERACT filter.

[1]  L. Coates,et al.  Development of a preliminary composite disease activity index in psoriatic arthritis , 2010, Annals of the rheumatic diseases.

[2]  B. Tom,et al.  Informing Response Criteria for Psoriatic Arthritis. I: Discrimination Models Based on Data from 3 Anti-Tumor Necrosis Factor Randomized Studies , 2010, The Journal of Rheumatology.

[3]  L. Coates,et al.  Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data , 2010, Arthritis care & research.

[4]  L. Coates,et al.  Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort , 2010, Arthritis care & research.

[5]  A. Kavanaugh,et al.  Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis , 2010, Annals of the rheumatic diseases.

[6]  J. Ortonne,et al.  Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial , 2010, BMJ : British Medical Journal.

[7]  L. Coates,et al.  Composite Measures in Psoriatic Arthritis: GRAPPA 2008 , 2010, The Journal of Rheumatology.

[8]  J. Smolen,et al.  Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis , 2009, Annals of the rheumatic diseases.

[9]  L. Coates,et al.  Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment , 2009, Annals of the rheumatic diseases.

[10]  A. Gottlieb,et al.  Treatment recommendations for psoriatic arthritis , 2008, Annals of the rheumatic diseases.

[11]  P. Mease Assessment tools in psoriatic arthritis. , 2008, The Journal of rheumatology.

[12]  D. Gladman,et al.  International spondyloarthritis interobserver reliability exercise--the INSPIRE study: I. Assessment of spinal measures. , 2007, The Journal of rheumatology.

[13]  D. Gladman,et al.  International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. , 2007, The Journal of rheumatology.

[14]  A. Gottlieb,et al.  Consensus on a core set of domains for psoriatic arthritis. , 2007, The Journal of rheumatology.

[15]  W. Uter,et al.  Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors , 2006, Annals of the rheumatic diseases.

[16]  P. Mease,et al.  Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. , 2006, Journal of the American Academy of Dermatology.

[17]  A. Kavanaugh,et al.  Outcome measures in psoriatic arthritis , 2005, Current rheumatology reports.

[18]  S. Feldman,et al.  Psoriasis assessment tools in clinical trials , 2005, Annals of the rheumatic diseases.

[19]  D. Gladman,et al.  Psoriatic arthritis assessment tools in clinical trials , 2005, Annals of the rheumatic diseases.

[20]  D. Gladman,et al.  Psoriatic arthritis imaging: a review of scoring methods , 2005, Annals of the rheumatic diseases.

[21]  D. Reda,et al.  Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. , 1996, Arthritis and rheumatism.

[22]  R. Francis,et al.  A comparison of the effectiveness and cost of treatment for vertebral fractures in women. , 1995, British journal of rheumatology.

[23]  K. Kalunian,et al.  The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. , 2007, The Journal of rheumatology.

[24]  D. Gladman,et al.  International spondyloarthritis inter-observer reliability exercise - The inspire study , 2006 .

[25]  D. Gladman,et al.  Assessment of patients with psoriatic arthritis: a review of currently available measures. , 2004, Arthritis and rheumatism.